INOVIQ Ltd (IIQ.AX)
- Previous Close
0.5350 - Open
0.5300 - Bid 0.5250 x --
- Ask 0.5350 x --
- Day's Range
0.5250 - 0.5350 - 52 Week Range
0.4650 - 0.9900 - Volume
24,001 - Avg. Volume
109,940 - Market Cap (intraday)
48.31M - Beta (5Y Monthly) 2.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Feb 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.
www.inoviq.comRecent News: IIQ.AX
Performance Overview: IIQ.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IIQ.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IIQ.AX
Valuation Measures
Market Cap
48.31M
Enterprise Value
42.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
111.87
Price/Book (mrq)
2.89
Enterprise Value/Revenue
99.36
Enterprise Value/EBITDA
-5.31
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.14%
Return on Equity (ttm)
-32.85%
Revenue (ttm)
1.58M
Net Income Avi to Common (ttm)
-6.51M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
5.97M
Total Debt/Equity (mrq)
3.41%
Levered Free Cash Flow (ttm)
-3.45M
Company Insights: IIQ.AX
IIQ.AX does not have Company Insights